Assembly Biosciences Inc (ASMB) Position Cut by Orbimed Advisors LLC
Orbimed Advisors LLC trimmed its position in Assembly Biosciences Inc (NASDAQ:ASMB) by 15.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 748,026 shares of the biopharmaceutical company’s stock after selling 140,400 shares during the quarter. Orbimed Advisors LLC owned 3.75% of Assembly Biosciences worth $26,121,000 at the end of the most recent reporting period.
A number of other large investors have also recently made changes to their positions in ASMB. Nationwide Fund Advisors bought a new position in Assembly Biosciences in the second quarter valued at approximately $161,000. Parametric Portfolio Associates LLC grew its stake in shares of Assembly Biosciences by 13.6% during the second quarter. Parametric Portfolio Associates LLC now owns 10,078 shares of the biopharmaceutical company’s stock worth $208,000 after buying an additional 1,203 shares during the last quarter. Legal & General Group Plc bought a new stake in shares of Assembly Biosciences during the second quarter worth $212,000. Wells Fargo & Company MN bought a new stake in shares of Assembly Biosciences during the second quarter worth $213,000. Finally, Trexquant Investment LP bought a new stake in shares of Assembly Biosciences during the second quarter worth $217,000. 62.09% of the stock is currently owned by institutional investors and hedge funds.
ASMB has been the topic of a number of research reports. Zacks Investment Research cut shares of Assembly Biosciences from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. BidaskClub raised shares of Assembly Biosciences from a “hold” rating to a “buy” rating in a research note on Friday, August 18th. Chardan Capital reaffirmed a “buy” rating on shares of Assembly Biosciences in a research note on Sunday, September 17th. Jefferies Group initiated coverage on shares of Assembly Biosciences in a research note on Wednesday, November 8th. They set a “buy” rating and a $50.00 target price on the stock. Finally, ValuEngine cut shares of Assembly Biosciences from a “hold” rating to a “sell” rating in a research note on Thursday. One analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $40.67.
In other Assembly Biosciences news, Director William R. Ringo sold 1,000 shares of the business’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $49.37, for a total transaction of $49,370.00. Following the sale, the director now owns 20,465 shares of the company’s stock, valued at $1,010,357.05. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In the last ninety days, insiders have sold 3,000 shares of company stock worth $112,620. Insiders own 19.60% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/10/assembly-biosciences-inc-asmb-position-cut-by-orbimed-advisors-llc.html.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Receive News & Stock Ratings for Assembly Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc and related stocks with our FREE daily email newsletter.